HMOs: A window of opportunity or a weapon in strengthening immunity

HMOs stimulate the development of a bifidogenic microbiome, which is boosting
a maturation of the immune system into a balanced TH1/TH2 development resulting
in a reduced risk of allergic disease.

Currently there is scientific evidence linking HMOs and more particularly 2 FL and LNnT
with the prevention of allergic sensitization. The results both from preclinical and clinical
observational data, from the LIFE Child Cohort, demonstrates a positive effect of 2FL and
LNnT in reduction of allergic sensitization.

2’FL and LNnT are among the most studied HMOs with clinical evidence to support
immunity and the developing microbiome. Latest research on additional HMOs in human milk & beyond show promise in expanded benefits on gut, immune, brain and bone health.

Human milk oligosaccharides (HMOs) are the third most abundant component of human milk excluding water. Its concentration ranges from 5 to 15 g/L in mothers’ milk and has implications in wide-ranging health outcomes of the new-born.

Human milk oligosaccharides (HMOs) are a group of complex carbohydrates that are highly
abundant in human milk and contribute to shaping the infant’s gut microbiome and immune system for immediate and long-term health benefits.